An Open–Label, Randomized, Multi–Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin–2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma

An Open–Label, Randomized, Multi–Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin–2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma

Combination immunotherapy with sequential administration may enhance metastatic melanoma (MM) patients with long-term disease control. High Dose Aldesleukin/Recombinant Interleukin-2 (HD rIL-2) and ipilimumab (IPI) offer complementary mechanisms against MM. This phase IV study assessed the sequenced...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Merve Hasanov, Denái R. Milton, William H. Sharfman, Bret Taback, Lee D. Cranmer, Gregory A Daniels, Lawrence Flaherty, Sigrun Hallmeyer, Mohammed Milhem, Lynn Feun, Ralph Hauke, Gary Doolittle, Nancy Gregory, Sapna Patel
Formato: article
Lenguaje:EN
Publicado: Taylor & Francis Group 2021
Materias:
metastatic melanoma
ipilimumab
high dose interleukin-2
clinical trial
Immunologic diseases. Allergy
RC581-607
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/8301b9196dbd4b3ab906e344ff9c4301
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/8301b9196dbd4b3ab906e344ff9c4301

Ejemplares similares